Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2023 07:00 ET | Source: HilleVax, Inc.

HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
September 19, 2023 20:05 ET | Source: HilleVax, Inc.

HilleVax Announces Pricing of Public Offering of Common Stock

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
September 19, 2023 16:09 ET | Source: HilleVax, Inc.

HilleVax Announces Proposed Public Offering of Common Stock

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
August 14, 2023 07:00 ET | Source: HilleVax, Inc.

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
May 12, 2023 16:05 ET | Source: HilleVax, Inc.

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
May 09, 2023 07:00 ET | Source: HilleVax, Inc.

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
April 25, 2023 06:45 ET | Source: HilleVax, Inc.

HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024 HIL-214 is the most advanced vaccine candidate for norovirus infection There are currently no approved...
March 17, 2023 16:05 ET | Source: HilleVax, Inc.

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported...
January 09, 2023 07:00 ET | Source: HilleVax, Inc.

HilleVax Announces Executive Management Appointments and Promotions

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
January 04, 2023 16:05 ET | Source: HilleVax, Inc.

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right